Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$3.14 +0.3%	$3.55	$1.24 ▼ $4.08	$832.56M	0.96	4.29 million shs	2.51 million shs
GNFT GENFIT	$3.89 -4.2%	$3.91	$2.55 ▼ $6.42	$200.01M	1.14	3,790 shs	1,234 shs
QURE uniQure	$16.33 +0.4%	$14.67	$4.45 ▼ $19.18	$895.98M	0.11	832,373 shs	710,727 shs
SANA Sana Biotechnology	$3.06 +1.7%	$3.69	$1.26 ▼ $7.30	$727.69M	1.9	6.30 million shs	3.26 million shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	0.00%	-1.57%	-14.67%	+3.63%	+105.23%
GNFT GENFIT	0.00%	-9.85%	+1.46%	-11.16%	-7.66%
QURE uniQure	0.00%	+4.01%	+17.31%	+12.16%	+169.25%
SANA Sana Biotechnology	0.00%	-14.53%	-24.63%	+41.67%	-47.69%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKBA Akebia Therapeutics	3.756 of 5 stars	3.5	2.0	4.0	2.1	0.8	0.6
GNFT GENFIT	1.9207 of 5 stars	3.5	3.0	0.0	2.8	0.0	0.0
QURE uniQure	2.3625 of 5 stars	3.5	1.0	0.0	2.6	2.5	0.6
SANA Sana Biotechnology	2.8785 of 5 stars	3.5	3.0	0.0	1.5	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	3.00	Buy	$6.75	114.97% Upside
GNFT GENFIT	3.00	Buy	$9.00	131.30% Upside
QURE uniQure	3.00	Buy	$37.45	129.36% Upside
SANA Sana Biotechnology	3.00	Buy	$8.00	161.44% Upside

Current Analyst Ratings Breakdown

Latest GNFT, QURE, SANA, and AKBA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/29/2025	QURE uniQure	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
8/19/2025	GNFT GENFIT	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$9.00
8/14/2025	QURE uniQure	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$30.00
8/13/2025	AKBA Akebia Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/30/2025	QURE uniQure	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$47.00
7/29/2025	QURE uniQure	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$38.00 ➝ $35.00
7/3/2025	SANA Sana Biotechnology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$12.00
6/24/2025	SANA Sana Biotechnology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00
6/4/2025	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00

(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$160.18M	5.20	N/A	N/A	$0.11 per share	28.55
GNFT GENFIT	$76.77M	2.53	$0.07 per share	57.19	$1.50 per share	2.59
QURE uniQure	$27.12M	33.04	N/A	N/A	($0.07) per share	-233.29
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$0.52 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$69.41M	-$0.17	N/A	N/A	N/A	-17.91%	N/A	-13.47%	11/6/2025 (Estimated)
GNFT GENFIT	$1.63M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/22/2025 (Estimated)
QURE uniQure	-$239.56M	-$3.92	N/A	N/A	N/A	-1,387.98%	-1,010.74%	-33.27%	11/4/2025 (Estimated)
SANA Sana Biotechnology	-$266.76M	-$1.06	N/A	N/A	N/A	N/A	-91.96%	-43.07%	11/14/2025 (Estimated)

Latest GNFT, QURE, SANA, and AKBA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/11/2025	Q2 2025	SANA Sana Biotechnology	-$0.20	-$0.16	+$0.04	-$0.39	N/A	N/A
7/29/2025	Q2 2025	QURE uniQure	-$0.89	-$0.69	+$0.20	-$0.69	$5.00 million	$5.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
GNFT GENFIT	N/A	N/A	N/A	N/A	N/A
QURE uniQure	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	1.61	1.98	1.84
GNFT GENFIT	0.08	1.23	1.23
QURE uniQure	1.53	9.98	9.98
SANA Sana Biotechnology	N/A	2.47	2.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
GNFT GENFIT	2.24%
QURE uniQure	78.83%
SANA Sana Biotechnology	88.23%

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	3.00%
GNFT GENFIT	4.20%
QURE uniQure	4.79%
SANA Sana Biotechnology	30.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	430	265.14 million	257.19 million	Optionable
GNFT GENFIT	120	50.00 million	47.90 million	Not Optionable
QURE uniQure	500	54.87 million	52.24 million	Optionable
SANA Sana Biotechnology	380	237.81 million	166.23 million	Optionable

GNFT, QURE, SANA, and AKBA Headlines

Recent News About These Companies

Sana Biotechnology Announces Public Offering Pricing

August 28 at 12:46 AM | theglobeandmail.com

Sana Biotechnology to Present at September 2025 Investor Conferences

August 26, 2025 | globenewswire.com

Deutsche Bank AG Has $1.12 Million Stock Holdings in Sana Biotechnology, Inc. $SANA

August 26, 2025 | marketbeat.com

Citizens JMP Reiterates a Buy Rating on Sana Biotechnology (SANA) With a $5 PT

August 25, 2025 | msn.com

Biotech’s Big Bang: IPOs, Uplists, and the Short Squeeze Effect

August 21, 2025 | msn.com

Sana Biotechnology Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares

August 21, 2025 | uk.finance.yahoo.com

Sana Biotechnology Announces Closing of Full Exercise of Underwriters’ Option to Purchase ...

August 21, 2025 | bakersfield.comB

Sana Biotechnology Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares

August 20, 2025 | tmcnet.com

Sana Biotechnology, Inc. Completes Sale of 3,358,208 Shares, Generating Approximately $86.3 Million in Gross Proceeds

August 20, 2025 | quiverquant.comQ

HC Wainwright Issues Optimistic Forecast for SANA Earnings

August 16, 2025 | marketbeat.com

Sana Biotechnology drops Washington plant build-out, pivots to CDMOs instead

August 14, 2025 | fiercepharma.comF

Sana Biotechnology Reports Non-Cash Impairment Losses

August 14, 2025 | theglobeandmail.com

Sana Biotech Bails on Factory in Old AT&T Call Center

August 12, 2025 | finance.yahoo.com

Sana Biotechnology (NASDAQ:SANA) Posts Earnings Results, Beats Estimates By $0.04 EPS

August 12, 2025 | marketbeat.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Rating of "Buy" by Brokerages

August 12, 2025 | marketbeat.com

Sana: Q2 Earnings Snapshot

August 11, 2025 | sfgate.com

Sana suspends build-out of Bothell manufacturing facility

August 11, 2025 | bizjournals.com

Sana Biotechnology Reports Second Quarter 2025 Financial Results and Business Updates

August 11, 2025 | manilatimes.netM

Sana Biotechnology: Fundraising Triggers Major Sell-Off, I'm Still Intrigued

August 8, 2025 | seekingalpha.com

Sana Biotechnology (NASDAQ:SANA) Shares Gap Down - Here's What Happened

August 8, 2025 | marketbeat.com

Seattle biotech firm Sana Biotechnology raising $75 million through public offering

August 8, 2025 | bizjournals.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNFT, QURE, SANA, and AKBA Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$3.14 +0.01 (+0.32%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$3.12 -0.02 (-0.48%)

As of 08/29/2025 07:44 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

GENFIT NASDAQ:GNFT

$3.87 -0.19 (-4.68%)

As of 08/29/2025 04:00 PM Eastern

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

uniQure NASDAQ:QURE

$16.33 +0.07 (+0.43%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$16.58 +0.25 (+1.53%)

As of 08/29/2025 06:42 PM Eastern

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Sana Biotechnology NASDAQ:SANA

$3.06 +0.05 (+1.66%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$3.10 +0.04 (+1.47%)

As of 08/29/2025 07:51 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time